Incontinence Associated Dermatitis

This session provides a review of the current state of knowledge about incontinence associated dermatitis.

Contact hours available until 3/7/2015.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Conflict of Interest Disclosure:
Planning Committee Disclosures:

Donna J. Carrico, WHNP, MS/ Consultant/Presenter Bureau: Uroplasty Inc.
Tamara Dickinson, RN, CURN, CCCN, BCB-PMD/ Advisory Board:Hollister Inc, Seek Wellness

Speaker Disclosures:
Donna Z. Bliss, PhD, RN, FAAN, FGSA has disclosed the following relevant relationships with commercial interests:
Grant/Research Support: pending Subcontract from Eden Medical for NIH funded SBRI
Consultant/Presenter Bureau: 3M Consultant:Clinical Research Design
Travel and honorarim from U of Tokyo CON who had an educational grant from Convatec japan to fund my participation in their conference

There are no other disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Non-Endorsement of Products:
Accreditation of activities for contact hours does not imply approval or endorsement of any product, advertising, or educational content by the Society of Urologic Nurses and Associates (SUNA) or the American Nurses Credentialing Center’s Commission on Accreditation.

Accreditation Statement:
Society of Urologic Nurses and Associates is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Accreditation status does not imply endorsement by the provider or ANCC of any commercial product.

SUNA is a provider approved by the California Board of Registered Nursing, provider number, CEP 5556.

Objectives:

• Explain the epidemiology of IAD in different healthcare settings.
• Describe the manifestations of IAD.
• Discuss the etiology of IAD.
• Identify clinical tools for assessing IAD.
• Discuss recommendations for prevention and management of IAD.
• Examine costs of IAD and cost effective strategies of prevention/management products.